nach oben

Erschienen in:

11.12.2023 | Tumorchirurgie | Zertifizierte Fortbildung

Hepatologie - Teil 6: Maligne Tumoren der Leber

Diagnose, Staging und Therapieverfahren des hepatozellulären Karzinoms

verfasst von: PD Dr. med. Ursula Ehmer, PhD

Erschienen in: Gastro-News | Ausgabe 6/2023

zum CME-Kurs Einloggen, um Zugang zu erhalten

Auszug

Das hepatozelluläre Karzinom (HCC) ist das häufigste primäre Lebermalignom mit steigender Inzidenz in der westlichen Welt. Trotz der immer noch eingeschränkten Prognose hat sich das Überleben durch Fortschritte in der Therapie in den letzten Jahren entscheidend verbessert. Die multidisziplinäre, stadienadaptierte Therapie des HCC umfasst neben chirurgischen Therapieverfahren wie Resektion und Transplantation multiple lokoregionäre Therapieverfahren, darunter die Ablation oder transarterielle Verfahren. Nicht zuletzt hat die Verfügbarkeit neuer systemischer Therapieoptionen zu einer Verbesserung der Prognose im fortgeschrittenen Stadium beigetragen. …

Vogel A, Meyer T, Sapisochin G et al. Hepatocellular carcinoma. Lancet. 2022;400:1345-62

Ferlay J, Colombet M, Soerjomataram I et al. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021: Apr 5. doi: 10.1002/ijc.33588. Online ahead of print.

Shiels MS, O'Brien TR. Recent Decline in Hepatocellular Carcinoma Rates in the United States. Gastroenterology. 2020 Apr;158(5):1503-5.e2

Voesch S, Bitzer M, Blodt S et al. S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms und biliärer Karzinome - Version 2.0 - Juni 2021, AWMF-Registernummer: 032-053OL Z Gastroenterol 2022;60:e131-e85

European Association for the Study of the Liver E. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236

Di Martino M, De Filippis G, De Santis A et al. Hepatocellular carcinoma in cirrhotic patients: prospective comparison of US, CT and MR imaging. Eur Radiol. 2013;23:887-96

Lee YJ, Lee JM, Lee JS et al. Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis. Radiology. 2015;275:97-109

Aube C, Oberti F, Lonjon J et al. EASL and AASLD recommendations for the diagnosis of HCC to the test of daily practice. Liver Int. 2017;37:1515-25

Lee YT, Wang JJ, Zhu Y et al. Diagnostic Criteria and LI-RADS for Hepatocellular Carcinoma. Clin Liver Dis (Hoboken). 2021;17:409-13

10.

Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329-38

11.

Reig M, Forner A, Rimola J et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76:681-93

12.

Zhou Y, Lei X, Wu L et al. Outcomes of hepatectomy for noncirrhotic hepatocellular carcinoma: a systematic review. Surg Oncol. 2014;23:236-42

13.

Citterio D, Facciorusso A, Sposito C et al. Hierarchic Interaction of Factors Associated With Liver Decompensation After Resection for Hepatocellular Carcinoma. JAMA Surg. 2016;151:846-53

14.

Reveron-Thornton RF, Teng MLP, Lee EY et al. Global and regional long-term survival following resection for HCC in the recent decade: A meta-analysis of 110 studies. Hepatol Commun. 2022;6:1813-26

15.

Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-9

16.

Yao FY, Ferrell L, Bass NM et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394-403

17.

Bhoori S, Sposito C, Germini A et al. The challenges of liver transplantation for hepatocellular carcinoma on cirrhosis. Transpl Int. 2010;23:712-22

18.

Rubinstein MM, Kaubisch A, Kinkhabwala M et al. Bridging therapy effectiveness in the treatment of hepatocellular carcinoma prior to orthotopic liver transplantation. J Gastrointest Oncol. 2017;8:1051-5

19.

Wang Y, Luo Q, Li Y, Deng S et al. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinomas: a meta-analysis of randomized and nonrandomized controlled trials. PLoS One. 2014;9:e84484

20.

Uhlig J, Sellers CM, Stein SM, Kim HS. Radiofrequency ablation versus surgical resection of hepatocellular carcinoma: contemporary treatment trends and outcomes from the United States National Cancer Database. Eur Radiol. 2019;29:2679-89

21.

Shin SW, Ahn KS, Kim SW et al. Liver Resection Versus Local Ablation Therapies for Hepatocellular Carcinoma Within the Milan Criteria: A Systematic Review and Meta-analysis. Ann Surg. 2021;273:656-66

22.

Kang TW, Lim HK, Cha DI. Percutaneous ablation for perivascular hepatocellular carcinoma: Refining the current status based on emerging evidence and future perspectives. World J Gastroenterol. 2018;24:5331-7

23.

Peng ZW, Zhang YJ, Chen MS et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol. 2013;31:426-32

24.

Llovet JM, Real MI, Montana X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734-9

25.

Gao S, Yang Z, Zheng Z et al. Doxorubicin-eluting bead versus conventional TACE for unresectable hepatocellular carcinoma: a meta-analysis. Hepatogastroenterology. 2013;60:813-20

26.

Brown AM, Kassab I, Massani M et al. TACE versus TARE for patients with hepatocellular carcinoma: Overall and individual patient level meta analysis. Cancer Med. 2023;12(3):2590-99

27.

Kolligs FT, Bilbao JI, Jakobs T et al. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma. Liver Int. 2015;35:1715-21

28.

Dhondt E, Lambert B, Hermie L et al. (90)Y Radioembolization versus Drug-eluting Bead Chemoembolization for Unresectable Hepatocellular Carcinoma: Results from the TRACE Phase II Randomized Controlled Trial. Radiology. 2022;303:699-710

29.

Chow PKH, Gandhi M, Tan SB et al. SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. J Clin Oncol. 2018;36:1913-21

30.

Vilgrain V, Pereira H, Assenat E et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18:1624-36

31.

Feng M, Suresh K, Schipper MJ et al. Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage: A Phase 2 Clinical Trial. JAMA Oncol. 2018;4:40-7

32.

Finn RS, Qin S, Ikeda M et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382:1894-905

33.

Bruix J, Chan SL, Galle PR et al. Systemic treatment of hepatocellular carcinoma: An EASL position paper. J Hepatol. 2021;75:960-74

34.

Vogel A, Martinelli E, clinicalguidelines@esmo.org EGCEa, Committee EG. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Ann Oncol. 2021;32:801-5

35.

Kelley RK, Sangro B, Harris W et al. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. J Clin Oncol. 2021;39:2991-3001

36.

Haanen J, Obeid M, Spain L et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1217-38

37.

Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-90

38.

Kudo M, Finn RS, Qin S et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163-73

39.

Bruix J, Qin S, Merle P et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56-66

40.

Abou-Alfa GK, Meyer T, Cheng AL et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018;379:54-63

41.

Zhu AX, Park JO, Ryoo BY et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015;16:859-70

42.

Marrero JA, Kudo M, Venook AP et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. J Hepatol. 2016;65:1140-7

43.

Pinato DJ, Sharma R, Allara E et al. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. J Hepatol. 2017;66:338-46

Titel: Hepatologie - Teil 6: Maligne Tumoren der Leber
Diagnose, Staging und Therapieverfahren des hepatozellulären Karzinoms
verfasst von: PD Dr. med. Ursula Ehmer, PhD
Publikationsdatum: 11.12.2023
Verlag: Springer Medizin
Schlagwörter: Tumorchirurgie
Onkologische Therapie
Diagnostik in der Onkologie
Diagnostik in der Gastroenterologie
Hepatozelluläres Karzinom
Hepatozelluläres Karzinom
Leberzirrhose
Sorafenib
Lebertransplantation
Lebertransplantation
Lebertransplantation
Lebertransplantation
Lebertransplantation
Erschienen in: Gastro-News / Ausgabe 6/2023
Print ISSN: 1869-1005
Elektronische ISSN: 2520-8667
DOI: https://doi.org/10.1007/s15036-023-3327-7

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2023

Was bei Reizdarm und Unverträglichkeiten gesichert ist

Mukosaheilung verbessert langfristiges Outcome

Verbesserung von Fibrose oder NASH-Ausheilung mit FGF21-Faktor-Analogon?

Neue MRT-Verfahren zur NASH-Diagnostik

Klinisch in schwerem Fahrwasser - in der Forschung und Fortbildung Spitze

Anhaltendes virologisches Ansprechen mit Entry-Inhibitor